--- title: "Bavarian Nordic and SII sign agreement for chikungunya vaccine production" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278878090.md" description: "Bavarian Nordic and the Serum Institute of India (SII) have signed an agreement for the technology transfer of chikungunya vaccine production, enhancing capacity for low- and middle-income countries. This partnership builds on their existing collaboration for the mpox vaccine and replaces a previous deal with Biological E. The CHIKV VLP vaccine, marketed as Vimkunya, is approved by regulatory agencies in the UK, EU, and US, with ongoing reviews in Canada and Switzerland. The vaccine aims to improve global access and has shown a significant increase in demand due to rising disease cases in the UK." datetime: "2026-03-12T11:21:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278878090.md) - [en](https://longbridge.com/en/news/278878090.md) - [zh-HK](https://longbridge.com/zh-HK/news/278878090.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278878090.md) | [English](https://longbridge.com/en/news/278878090.md) # Bavarian Nordic and SII sign agreement for chikungunya vaccine production The vaccine is a single-dose, prefilled product for immunisation against the chikungunya virus in individuals aged 12 and above. Credit: Kitsawet Saethao / Shutterstock.com. Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries. ### Go deeper with GlobalData - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - Ebola \[Ankara Bavarian Nordic Strain\] (Multiva... - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - (plasmodium falciparum + hepatitis B) vaccine ##### Go deeper with GlobalData The gold standard of business intelligence. Find out more #### Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more The new arrangement builds upon the existing licence and manufacturing partnership between the two companies for the mpox vaccine. It replaces an earlier deal with Biological E. Both parties will also explore potential co-development opportunities as part of this extended collaboration. Bavarian Nordic’s president and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India. “By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe.” GlobalData Strategic Intelligence # US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunisation against disease caused by the chikungunya virus in people aged 12 years and above. It is designed to trigger a strong seroresponse, with protective immunity beginning to develop as soon as one week following vaccination. As it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad population demographic. Marketed as Vimkunya, CHIKV VLP has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) in 2025. Regulatory review is underway in Canada and Switzerland. In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK. The launch followed a significant increase in travel-related disease cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences rose by 170% in August 2025 compared with the same period in 2024. ### 相關股票 - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [Bavarian Nordic A/S (BVNRY.US)](https://longbridge.com/zh-HK/quote/BVNRY.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) ## 相關資訊與研究 - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-HK/news/281025352.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-HK/news/281024362.md) - [Bavarian Nordic Signs Distribution Agreement with Eurofarma for Chikungunya Vaccine in Brazil](https://longbridge.com/zh-HK/news/273475677.md) - [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-HK/news/281026919.md) - [09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy](https://longbridge.com/zh-HK/news/281030940.md)